Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists

L. T M Van der Ven, I. M. Prinsen, G. H. Jansen, P. J M Roholl, R. Defferrari, R. Slater, W. Den Otter

Research output: Contribution to journalArticle

Abstract

The 50% survival time for low grade astrocytomas is 50 months and for high grade astrocytomas it is 13 months, underlining the need for new therapies. Several reports show that in vivo histamine antagonists cause retardation of tumour growth in some animal models and prolonged survival in cancer patients. Therefore we have tested the growth modulating effects of histamine and histamine antagonists on human glioma cultures. Twelve freshly excised human gliomas were cultured and tested for their in vitro sensitivity to histamine and histamine antagonists. Four continuous glioma cell lines were used to confirm the glioma-specificity of the effects observed in the primary cell lines. In low serum concentration (0 or 1%) the growth of 5 9 primary glioma-derived cultures could be stimulated with 0.2 mm histamine, and in 4 5 cases with 0.2 μm histamine. One mm of the histamine HZ-receptor antagonist cimetidine could inhibit the growth of 4/5 primary glioma cultures when tested in 1 % human AB serum, and of 6 13 cases when tested in 1 % FCS. Lower concentrations (down to 1 μm) were less effective. The histamine H1-receptor antagonist pyrilamine gave variable results. The specificity of the effects is indicated by the absence of a generalised toxic effect, by the observation that the antagonist-induced inhibition could be reversed with histamine, and by the correlation of the obtained cimetidine-induced growth inhibition with the maximal growth rate of the primary cell lines in 10% FCS. The observed cimetidine-induced inhibition of the in vitro proliferation of gliomas suggests that cimetidine is a relevant candidate for the in vivo growth inhibition of these tumours.

Original languageEnglish
Pages (from-to)475-483
Number of pages9
JournalBritish Journal of Cancer
Volume68
Issue number3
Publication statusPublished - Sep 1993

Fingerprint

Histamine Antagonists
Glioma
Histamine
Cimetidine
Growth
Neoplasms
Astrocytoma
Cell Line
Histamine H1 Antagonists
Pyrilamine
Histamine Receptors
Survival
Poisons
Serum
Animal Models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Van der Ven, L. T. M., Prinsen, I. M., Jansen, G. H., Roholl, P. J. M., Defferrari, R., Slater, R., & Den Otter, W. (1993). Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. British Journal of Cancer, 68(3), 475-483.

Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. / Van der Ven, L. T M; Prinsen, I. M.; Jansen, G. H.; Roholl, P. J M; Defferrari, R.; Slater, R.; Den Otter, W.

In: British Journal of Cancer, Vol. 68, No. 3, 09.1993, p. 475-483.

Research output: Contribution to journalArticle

Van der Ven, LTM, Prinsen, IM, Jansen, GH, Roholl, PJM, Defferrari, R, Slater, R & Den Otter, W 1993, 'Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists', British Journal of Cancer, vol. 68, no. 3, pp. 475-483.
Van der Ven LTM, Prinsen IM, Jansen GH, Roholl PJM, Defferrari R, Slater R et al. Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. British Journal of Cancer. 1993 Sep;68(3):475-483.
Van der Ven, L. T M ; Prinsen, I. M. ; Jansen, G. H. ; Roholl, P. J M ; Defferrari, R. ; Slater, R. ; Den Otter, W. / Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. In: British Journal of Cancer. 1993 ; Vol. 68, No. 3. pp. 475-483.
@article{fdb0410ca0de4b3bab067efe118e22d6,
title = "Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists",
abstract = "The 50{\%} survival time for low grade astrocytomas is 50 months and for high grade astrocytomas it is 13 months, underlining the need for new therapies. Several reports show that in vivo histamine antagonists cause retardation of tumour growth in some animal models and prolonged survival in cancer patients. Therefore we have tested the growth modulating effects of histamine and histamine antagonists on human glioma cultures. Twelve freshly excised human gliomas were cultured and tested for their in vitro sensitivity to histamine and histamine antagonists. Four continuous glioma cell lines were used to confirm the glioma-specificity of the effects observed in the primary cell lines. In low serum concentration (0 or 1{\%}) the growth of 5 9 primary glioma-derived cultures could be stimulated with 0.2 mm histamine, and in 4 5 cases with 0.2 μm histamine. One mm of the histamine HZ-receptor antagonist cimetidine could inhibit the growth of 4/5 primary glioma cultures when tested in 1 {\%} human AB serum, and of 6 13 cases when tested in 1 {\%} FCS. Lower concentrations (down to 1 μm) were less effective. The histamine H1-receptor antagonist pyrilamine gave variable results. The specificity of the effects is indicated by the absence of a generalised toxic effect, by the observation that the antagonist-induced inhibition could be reversed with histamine, and by the correlation of the obtained cimetidine-induced growth inhibition with the maximal growth rate of the primary cell lines in 10{\%} FCS. The observed cimetidine-induced inhibition of the in vitro proliferation of gliomas suggests that cimetidine is a relevant candidate for the in vivo growth inhibition of these tumours.",
author = "{Van der Ven}, {L. T M} and Prinsen, {I. M.} and Jansen, {G. H.} and Roholl, {P. J M} and R. Defferrari and R. Slater and {Den Otter}, W.",
year = "1993",
month = "9",
language = "English",
volume = "68",
pages = "475--483",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists

AU - Van der Ven, L. T M

AU - Prinsen, I. M.

AU - Jansen, G. H.

AU - Roholl, P. J M

AU - Defferrari, R.

AU - Slater, R.

AU - Den Otter, W.

PY - 1993/9

Y1 - 1993/9

N2 - The 50% survival time for low grade astrocytomas is 50 months and for high grade astrocytomas it is 13 months, underlining the need for new therapies. Several reports show that in vivo histamine antagonists cause retardation of tumour growth in some animal models and prolonged survival in cancer patients. Therefore we have tested the growth modulating effects of histamine and histamine antagonists on human glioma cultures. Twelve freshly excised human gliomas were cultured and tested for their in vitro sensitivity to histamine and histamine antagonists. Four continuous glioma cell lines were used to confirm the glioma-specificity of the effects observed in the primary cell lines. In low serum concentration (0 or 1%) the growth of 5 9 primary glioma-derived cultures could be stimulated with 0.2 mm histamine, and in 4 5 cases with 0.2 μm histamine. One mm of the histamine HZ-receptor antagonist cimetidine could inhibit the growth of 4/5 primary glioma cultures when tested in 1 % human AB serum, and of 6 13 cases when tested in 1 % FCS. Lower concentrations (down to 1 μm) were less effective. The histamine H1-receptor antagonist pyrilamine gave variable results. The specificity of the effects is indicated by the absence of a generalised toxic effect, by the observation that the antagonist-induced inhibition could be reversed with histamine, and by the correlation of the obtained cimetidine-induced growth inhibition with the maximal growth rate of the primary cell lines in 10% FCS. The observed cimetidine-induced inhibition of the in vitro proliferation of gliomas suggests that cimetidine is a relevant candidate for the in vivo growth inhibition of these tumours.

AB - The 50% survival time for low grade astrocytomas is 50 months and for high grade astrocytomas it is 13 months, underlining the need for new therapies. Several reports show that in vivo histamine antagonists cause retardation of tumour growth in some animal models and prolonged survival in cancer patients. Therefore we have tested the growth modulating effects of histamine and histamine antagonists on human glioma cultures. Twelve freshly excised human gliomas were cultured and tested for their in vitro sensitivity to histamine and histamine antagonists. Four continuous glioma cell lines were used to confirm the glioma-specificity of the effects observed in the primary cell lines. In low serum concentration (0 or 1%) the growth of 5 9 primary glioma-derived cultures could be stimulated with 0.2 mm histamine, and in 4 5 cases with 0.2 μm histamine. One mm of the histamine HZ-receptor antagonist cimetidine could inhibit the growth of 4/5 primary glioma cultures when tested in 1 % human AB serum, and of 6 13 cases when tested in 1 % FCS. Lower concentrations (down to 1 μm) were less effective. The histamine H1-receptor antagonist pyrilamine gave variable results. The specificity of the effects is indicated by the absence of a generalised toxic effect, by the observation that the antagonist-induced inhibition could be reversed with histamine, and by the correlation of the obtained cimetidine-induced growth inhibition with the maximal growth rate of the primary cell lines in 10% FCS. The observed cimetidine-induced inhibition of the in vitro proliferation of gliomas suggests that cimetidine is a relevant candidate for the in vivo growth inhibition of these tumours.

UR - http://www.scopus.com/inward/record.url?scp=0027257132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027257132&partnerID=8YFLogxK

M3 - Article

C2 - 8353038

AN - SCOPUS:0027257132

VL - 68

SP - 475

EP - 483

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -